EGFR and hepatocellular carcinoma: To demonstrate hepatocyte-specific degradation, we again chose EGFR as a model system, as EGFR is overexpressed in HCC patients and we sought to compare the efficiency of GalNAc-LYTACs to M6Pn-LYTACs.